ARWR
ArrowheadANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
11
U.S. public peers
Grade Position
Above peers
vs peer average
ARWR vs peer average
94/100
ARWR vs. peer average (A vs. D)
Grade spread
A 1 · B 2 · C 1 · D 2 · F 5
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
IONS is the first available peer comparator.
Ionis is the closest commercial and indication-level comparator. TRYNGOLZA, like REDEMPLO, targets APOC3 and is approved for FCS; Ionis also received an expanded U.S. sHTG approval in June 2026. Its product revenue, payer access, pricing, prescription conversion, and broader-indication launch trajectory provide direct benchmarks for REDEMPLO and plozasiran [#IR-IONS-2026-06-24].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
ARWR
Arrowhead
IONS
Ionis
Grade
A
B
Momentum
16
17
Value
41
41
Sentiment
93
84
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs IONS
ARWR / IONS
Grade Position
Above peers
ARWR vs. peer average (A vs. D)
94/100
Momentum
16
IONSValue
41
ARWRSentiment
93
ARWRRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs ARWR
IONS is the first peer returned for this comparison set.